eMed and Aon Join Forces to Enhance Digital GLP-1 Health Programs for Employees

eMed and Aon Collaborate to Advance Employee Health

In a groundbreaking move, eMed®, a leader in Population Health technology, has announced a collaboration with Aon, a prominent global professional services firm, to provide comprehensive GLP-1 obesity management services tailored for Aon's U.S. workforce. This partnership aims to foster healthier lifestyles through increased accessibility to effective obesity treatment and support services.

A Transformative Partnership

This new initiative comes at a time when both companies are grappling with escalating healthcare costs and a growing public health crisis related to obesity. Recent data from Aon demonstrates the efficacy of GLP-1 therapy; it showed a notable seven percentage point decrease in the rise of medical expenditures in the second year following the implementation of GLP-1 treatment and a remarkable 44 percent reduction in hospitalization risks linked to major cardiovascular incidents.

Dr. Patrice Harris, CEO of eMed, expressed her excitement about this collaboration, stating, "We are thrilled to collaborate with Aon to bring our cutting-edge platform to their employees. Our platform is a science-based, all-in-one solution proven to deliver superior health outcomes for participants, while enabling employers to manage their spend on GLP-1s. Together with Aon, we're not just offering access to GLP-1s; we're ensuring they are used effectively to improve long-term employee health outcomes as demonstrated by Aon's groundbreaking analysis."

Comprehensive Support Beyond Medication

The partnership emphasizes that the success of GLP-1 medications relies heavily on a holistic approach that includes elements such as nutritional guidance, physical activity, and psychological support. Aon’s Chief Administration Officer, Lisa Stevens, mentioned that, "Our findings show that GLP-1s, when combined with holistic support, can deliver lasting health improvements. Making this investment is essential."

The emphasis on providing affordable and dignified access to GLP-1 therapies not only addresses personal health needs but also aims to create positive impacts on the economic front. This collaboration signifies a substantial step forward in addressing the obesity epidemic within corporate settings.

Innovative Solutions for Long-term Health

eMed's innovative platform enables users to engage in self-care by breaking down barriers typically associated with medication access and clinical care. As the roles of GLP-1 medications expand, so too does the need for data-driven strategies focused on curbing healthcare expenses effectively.

Dr. Michael Mina, Chief Science Officer at eMed, remarked, "We have an opportunity to shift the obesity trend in the U.S. at a macro level. Employers have long been champions of wellness, but most initiatives haven't materially moved the needle on population health. By addressing obesity through the lens of health equity and access, we can unlock positive economic ripple effects."

tthe Future of Healthcare with Technology

The collaboration between eMed and Aon embodies a forward-thinking model in corporate healthcare management. eMed's suite of services includes conducting at-home screenings facilitated by trained professionals, followed by personalized treatment plans. Employees, once screened and approved, will benefit from monthly prescriptions, 24/7 side-effect support, and weekly wellness check-ins, ensuring they remain engaged in their healthcare journey.

This partnership not only highlights eMed’s commitment to enhancing population health but also reflects Aon’s dedication to fostering a culture of wellness among its employees. The combined expertise of both organizations aims to revolutionize access to essential treatments and foster healthier living environments in workplaces across the nation.

For further information on eMed's initiatives and their exciting collaboration with Aon, please visit www.eMed.com.